For example, SAHA is a well-known pan-HDAC inhibitor that has been approved by the FDA in 2006 for treatment of advanced primary cutaneous T-cell lymphoma [60]. The gene discussed is HDAC9; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.